Status:
COMPLETED
Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters
Lead Sponsor:
Bayer
Conditions:
Pregnancy, Unplanned
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the impact of SH T00658ID (EV/DNG tablet) on hemostatic parameters in comparison to a reference oral contraceptive (OC) (SH D01155E) in a crossover design.
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Healthy female volunteers
Exclusion
- Pregnancy or lactation
- Any condition that might interfere with the outcome as all contraindications for OC use.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00318799
Start Date
April 1 2006
End Date
May 1 2007
Last Update
November 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dinox B.V.
Groningen, Netherlands, 9713GZ